Chemed (CHE) Stock May Trade Below Fair Value On Cash Flow

Chemed has delivered a solid year to date share price gain, which puts sharper focus on whether the current US$509.09 level lines up with the cash the business is expected to generate. With fresh expansion news from its Roto-Rooter unit in the mix, the key issue is how today’s valuation compares with the value implied by those cash flows.

• The stock is up 20.1% year to date, so anyone buying now is effectively betting that future cash flows can support this stronger market price.
• Roto-Rooter’s acquisition of a major California franchise adds exposure to roughly 11 million more residents, which may support expectations for broader and more durable cash generation from that segment.
• Prefer to judge Chemed on earnings? See why Chemed's 24.1x P/E tells a different valuation story.

The stock's next move may depend on whether that recent share price strength is fully backed by Chemed's intrinsic value based on its cash flows.

If you want more context around Chemed and other companies where valuation is anchored on projected cash generation, a focused screen of 29 high quality undervalued stocks is a useful next step.

Does Chemed Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here focuses on the cash Chemed can return to shareholders over time. Latest twelve month free cash flow is about $331.2 million, with projections assuming moderately growing cash generation rather than sharp swings up or down.

Those forward cash flows imply an intrinsic value that the DCF puts meaningfully above the current $509.09 share price. The Roto-Rooter expansion across California matters in that context because it increases the footprint serving roughly 11 million more residents, which helps explain why the market is willing to pay up but still prices Chemed below what the cash flow model supports. Find out what Chemed could be worth using our Discounted Cash Flow (DCF) estimate.

The Chemed Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Chemed's valuation puzzle leaves off and spell out the specific combinations of future growth, profitability and earnings power that would need to hold for the shares to be worth materially more or less than today’s price. They live on Simply Wall St's Community page. Rather than focusing on a single multiple or model estimate, each scenario lays out the assumptions behind its fair value so you can compare them with actual results as new data arrives.

One of the top community narratives on Chemed: 11% undervalued

"The current valuation reflects a view that Chemed may be undervalued relative to its guidance for higher adjusted EPS, sustained Roto Rooter EBITDA margins, and ongoing cash returns..."

Discover why this Narrative puts Chemed at 11% undervalued.

One more side of Chemed that could change your view

Chemed’s valuation story is only half the picture, because internal checks also flag potential weak spots in the business that are worth weighing before you decide what happens next. Take a closer look at 1 warning sign before settling on a valuation.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com